At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 5 enrolled
Drug / intervention
Belumosudil 200 mg tablet +2 moredrug
Likely dose
Belumosudil 200 mg tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, 2-part Study Designated to Assess the Absolute Bioavailability of KD025 and to Determine the Mass Balance Recovery, Metabolite Profile and Identification of Metabolite Structures for [14C]-KD025 in Healthy Male Subjects
In Brief
A Phase 1 clinical trial evaluating Belumosudil 200 mg tablet, [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose, and 1 other intervention for Autoimmune Diseases and Fibrosis. Completed, enrolled 5 participants across 1 site.
Detailed Summary
Human, absorption, metabolism and excretion study of belumosudil (KD025)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutoimmune Diseases, Fibrosis
CountriesUnited Kingdom
CollaboratorsQuotient Sciences
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
First PostedApr 2019
Primary CompletionMay 2019
TodayJul 2026
First PostedApr 9, 2019
Enrollment StartApr 5, 2019
Primary CompletionMay 20, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.2 years ago
Interventions
Belumosudil 200 mg tabletdrug
Belumosudil 200 mg tablet, development candidate
[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdosedrug
test investigational medicinal product
[14C]-KD025 200 mg capsuledrug
test investigational medicinal product